NCT06663319View on ClinicalTrials.gov

A Study of JNJ-89402638 for Metastatic Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

February 25, 2028

Study Completion Date

July 28, 2028

Conditions
Unresectable Metastatic Colorectal Cancer
Interventions
DRUG

JNJ-89402638

JNJ-89402638 will be administered.

Trial Locations (8)

28050

RECRUITING

Hosp Univ Hm Sanchinarro, Madrid

34232

RECRUITING

Florida Cancer Specialists, Sarasota

46256

RECRUITING

Community Health Network, Indianapolis

49546

RECRUITING

Start Midwest, Grand Rapids

80045

RECRUITING

University of Colorado Denver Anschultz Medical Campus, Aurora

03722

SUSPENDED

Severance Hospital Yonsei University Health System, Seoul

05505

SUSPENDED

Asan Medical Center, Seoul

08035

RECRUITING

Hosp Univ Vall D Hebron, Barcelona

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY